AVLN vs RZLT
AVLN: Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases. RZLT: Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
Side-by-side fundamentals
| Metric | AVLN | RZLT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $28.72 | $5.00 | |
| Market cap as of 2026-07-23 | $1.3B | $481M | |
| ROE as of 2026-07-23 | -63.8% | -58.8% | RZLT higher |
| ROA as of 2026-07-23 | -57.2% | -54.5% | RZLT higher |
| Debt / equity as of 2026-07-23 | 0.14 | 0.00 | RZLT lower |
| Beta as of 2026-07-23 | -0.12 | 0.58 | |
| 1-year return as of 2026-07-22 close | -1.6% | -6.9% | AVLN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.